요즈마 그룹 코리아요즈마 그룹 코리아
  • Korean
  • About
    • Chairman
    • Overview
    • People
      • Team
      • Advisors & Partners
  • Business
  • YIC
  • Portfolio
  • Newsroom
  • Contact
Press enter to begin your search

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

yozmakorea 2022-06-08 June 27th, 2022

Alpha Tau Announces FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC

https://www.prnewswire.com/news-releases/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-pivotal-study-of-alpha-dart-in-recurrent-cutaneous-scc-301564017.html
News No Comments
Share Tweet Share Pin

Seoul Address
5F, SB Tower, 318 Dosan-daero, Gangnam-Gu, Seoul 06054, Republic of Korea

 +82-2-6949-5350   
 [email protected]

© 2023 요즈마 그룹 코리아.

  • Korean
  • About
    • Chairman
    • Overview
    • People
      • Team
      • Advisors & Partners
  • Business
  • YIC
  • Portfolio
  • Newsroom
  • Contact
Yozma Group Korea Co., Ltd

Seoul Address
5F, SB Tower, 318 Dosan-daero, Gangnam-Gu, Seoul 06054, Republic of Korea


 +82-2-6949-5350   
 [email protected]